According to the Complaint, Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of Vascepa, a brand-name prescription drug, primarily used to treat heart disease.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the Complaint alleges Defendants made false and misleading statements and/or failed to disclose that: (i) there was an increasingly high risk that certain of Amarin’s patents would be invalidated; (ii) the Company’s litigation was preventing it from effectuating a successful takeover; (iii) Defendants were downplaying the true threat the ongoing Abbreviated New Drug Applications ("ANDA") litigation posed to the Company’s business and future prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On October 27, 2022, the Court issued an Order consolidating cases and appointing Lead Plaintiff and Counsel. All future docketing was ordered to be done in the lead case 21-CV-19212.

On January 13, 2023, Lead Plaintiff filed an amended consolidated Complaint.